Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously. It has demonstrated significant efficacy in clinical weight loss trials and offers enhanced metabolic benefits compared to single-receptor therapies.
Concentration
10-30 mg/mL
Duration
Approx. 4-40+ weeks depending on vial size and titration
Key Benefits
Related Peptides
Peptide TherapyAOD-9604
Weight management peptide focused on fat metabolism support
$295+
Peptide TherapyMOTS-c
Metabolic efficiency and energy utilization peptide
$325+
Peptide Therapy5-Amino-1MQ
Metabolic support peptide for body composition and wellness optimization
$165+
Peptide TherapyRetatrutide
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. By engaging three metabolic pathways, it represents the next generation of weight management therapies with the potential for greater efficacy in both weight loss and metabolic improvement.
$249+
Prescription therapies require medical evaluation and supervision. Results vary. Side effects and risks are discussed during consultation.